Association of liver fibrosis‐4 index with adverse outcomes in hypertrophic cardiomyopathy patients

Association of liver fibrosis‐4 index with adverse outcomes in hypertrophic cardiomyopathy patients

Aims The fibrosis‐4 index (FIB‐4) is a non‐invasive tool to assess fibrosis risk in chronic liver disease. We aimed to explore the relationship between the FIB‐4 index and long‐term major adverse cardiovascular events (MACE) in HCM patients. Methods and results Consecutive patients diagnosed with HC...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ESC Heart Failure 2024-12, Vol.11 (6), p.3934-3945
Hauptverfasser: Abdu, Fuad A., Mareai, Redhwan M., Xiang, Lanqing, Galip, Jassur, Mohammed, Abdul‐Quddus, Zhang, Wen, Liu, Lu, Wang, Chunyue, Mohammed, Ayman A., Yin, Guoqing, Lv, Xian, Xu, Yawei, Che, Wenliang
Format: Artikel
Sprache:eng
Schlagworte:
Aged
Cardiac arrhythmia
Cardiology
Cardiomyopathy
Cardiomyopathy, Hypertrophic - complications
Cardiomyopathy, Hypertrophic - diagnosis
Cardiomyopathy, Hypertrophic - physiopathology
Cardiovascular disease
Clinical outcomes
Family medical history
Female
Fibrosis‐4 index
Follow-Up Studies
Heart failure
Hospitals
Humans
Hypertrophic cardiomyopathy
Laboratories
Liver cirrhosis
Liver Cirrhosis - complications
Liver Cirrhosis - diagnosis
Liver Cirrhosis - epidemiology
Liver fibrosis
Male
Medical imaging
Middle Aged
Mortality
Original
Patients
Prognosis
Retrospective Studies
Risk Assessment - methods
Risk Factors
Survival Rate - trends
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aims The fibrosis‐4 index (FIB‐4) is a non‐invasive tool to assess fibrosis risk in chronic liver disease. We aimed to explore the relationship between the FIB‐4 index and long‐term major adverse cardiovascular events (MACE) in HCM patients. Methods and results Consecutive patients diagnosed with HCM were included. Patients were divided into two groups using a defined cutoff value established through a ROC analysis for predicting MACE (FIB‐4 ≥ 2.37 and FIB‐4 
ISSN:2055-5822
2055-5822
DOI:10.1002/ehf2.14977